arrow
G

Guillaume Nicolas

centre de référence des maladies neuromusculaires nord-est-ile de france
H指数:43
被引数:5,871

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Electrophysiological assessment of motor unit loss in adult spinal muscular atrophy types III and IV: a multicenter national study comparing MUNIX, CMAP, and MUSIX

成人脊髓性肌萎缩症III型和IV型的运动单位丢失的电生理评估:一项比较MUNIX、CMAP和MUSIX的多中心国家研究

2026-03-020
PRE
Systematic review and meta-analysis of the efficacy and safety of [177Lu]Lu-edotreotide ([177Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors

系统评价和荟萃分析:[177Lu]Lu-edotreotide([177Lu]Lu-DOTATOC)治疗神经内分泌肿瘤的疗效与安全性

2025-11-080
OAAI
First-in-human administration of [61Cu]Cu-NODAGA-LM3 and head-to-head comparison with [68Ga]Ga-DOTA-TOC PET/CT as part of the phase I/II COPPER PET in NET study

首次人体给药的[⁶¹Cu]Cu-NODAGA-LM3及其与[⁶⁸Ga]Ga-DOTA-TOC PET/CT的头对头比较,作为NET研究中的COPPER PET I/II期试验的一部分

2025-05-240
OA
Spinal muscular atrophy is also a disorder of spermatogenesis
2024-12-200
OAAI
First-in-human administration of [161Tb]Tb-SibuDAB and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study
2024-12-050
OAAI
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
2024-03-264
OAAI
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum
2024-03-077
OAAI
Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study
2023-12-016
OAAI
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours

[177Lu]Lu-satoreotide tetraxetan在晚期生长抑素受体阳性神经内分泌肿瘤中的安全性和有效性的I/II期研究

2023-09-1812
OAAI
Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy
BRAIN
IF11.7
2021-04-208
OAAI